(MENAFN- ProactiveInvestors - UK) Gene therapy specialist Silence Therapeutics plc (LON:SLN) has bolstered its expertise at the top with two new appointments.
Dr Dmitry Samarsky becomes chief scientific officer (CSO) as of September 14 and Dr Andy Richards CBE becomes a non-executive director with immediate effect.
During his career, Samarsky has authored numerous articles in high impact scientific journals, book chapters and patents and presented, chaired and advised on RNA Therapeutics at more than 100 international scientific conferences.
Widely recognised as an expert in the oligonucleotide field, he joins from OliX Pharmaceuticals where he held the position as Senior VP of Technology and Global Business Development.
Cambridge graduate Dr Richards is an entrepreneur and investor in the biotechnology sector.
He is currently chairman of several UK biotechnology companies, including AIM listed medical imaging and digital health provider, IXICO Plc, Abcodia Ltd, Congenica Ltd and Babraham Bioscience Technologies Ltd.
On Samarsky, Silence chief executive Ali Mortazavi said: "We have undertaken an extensive search to find a CSO with experience in RNA therapeutics and are pleased to have recruited Dmitry, who brings a combination of deep technical expertise and commercial knowledge to Silence.
"Dmitry will be key in leading our efforts as we increase our liver focus and R & D in conjugated siRNAs. I look forward to working closely with him."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.